Phase II study of PS341 (VELCADE [bortezomib]) in myelodysplastic syndromes (MDS). EudraCT Number 2004-002935-23

Trial Profile

Phase II study of PS341 (VELCADE [bortezomib]) in myelodysplastic syndromes (MDS). EudraCT Number 2004-002935-23

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 09 Nov 2008 Planned end date changed to 1 Mar 2008 as reported by ClinicalTrials.gov.
    • 10 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top